Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma

Purpose: Rearrangements involving the MYC protooncogene are common in newly diagnosed multiple myeloma, but their prognostic significance is still unclear. The purpose of this study was to assess the impact of MYC rearrangement on clinical characteristics, treatment response, and survival in patients with newly diagnosed multiple myeloma. Experimental Design: This is a retrospective study including 1,342 patients seen in Mayo Clinic in Rochester, MN, from January 2006 to January 2018, who had cytogenetic testing by FISH at diagnosis, including MYC testing using the break apart FISH probe (8q24.1). Results: A rearrangement involving MYC was found in 8% of patients and was associated with elevated β2-microglobulin, ≥50% bone marrow plasma cells, IgA multiple myeloma, and the cooccurrence of trisomies. There were no differences in overall response rates between patients with and without MYC rearrangement when induction chemotherapy was proteasome inhibitor (PI)-based, immunomodulatory drug (IMiD)-based or PI + IMiD-based. Overall survival was shorter in patients with MYC rearrangement compared with patients without MYC rearrangement (5.3 vs. 8.0 years, P < 0.001). MYC rearrangement was associated with increased risk of death on multivariate analysis when high-risk cytogenetic abnormalities, ISS stage III, and ≥70 years of age were included (risk ratio: 1.5; P = 0.007). Conclusions: MYC rearrangement is associated with high disease burden and is an independent adverse prognostic factor in patients with newly diagnosed multiple myeloma.

[1]  P. L. Bergsagel,et al.  Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma , 2019, Blood Cancer Journal.

[2]  Caleb K. Stein,et al.  MYC dysregulation in the progression of multiple myeloma , 2019, Leukemia.

[3]  G. Morgan,et al.  Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma , 2019, Haematologica.

[4]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[5]  T. Klausen,et al.  Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma , 2016, Leukemia & lymphoma.

[6]  R. Orlowski,et al.  Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma , 2015, Leukemia & lymphoma.

[7]  G. Morgan,et al.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients , 2014, Blood Cancer Journal.

[8]  J. Keats,et al.  Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma , 2014, Leukemia.

[9]  G. Mulligan,et al.  Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma , 2011, Leukemia.

[10]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[11]  B. Barlogie,et al.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[12]  B. Hoffman,et al.  Apoptotic signaling by c-MYC , 2008, Oncogene.

[13]  E. Prochownik c-Myc: linking transformation and genomic instability. , 2008, Current molecular medicine.

[14]  P. L. Bergsagel,et al.  Characterization of MYC translocations in multiple myeloma cell lines. , 2008, Journal of the National Cancer Institute. Monographs.

[15]  B. Barlogie,et al.  Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors , 2008, Genes, chromosomes & cancer.

[16]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[17]  P. L. Bergsagel,et al.  A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy , 2007, Leukemia.

[18]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[19]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[20]  R. Bataille,et al.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. , 2001, Blood.

[21]  U. Weidle,et al.  Control of cell growth by c-Myc in the absence of cell division , 1999, Current Biology.

[22]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.